Discussions

Digital therapeutics - the increasing regulatory support has facilitated the establishment of a standard developmental pathway for these solutions

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes.
The global digital therapeutics market size is estimated to grow from USD 2.83 billion in 2024 to USD 19.76 billion by 2035, representing a CAGR of 19.32% during the forecast period till 2035.
Several organizations have undertaken diverse initiatives in the field of digital therapeutics to support its growth as a new frontier in the healthcare sector. A number of organizations focused on effectively monitoring and promoting the potential of digital therapeutics to be used as a part of strategies to improve the population health have also been established. These organizations include:
 Digital Therapeutics Alliance (DTA)
 Personal Connected Health (PCH) Alliance
 Centers for Disease Control and Prevention (CDC)
 Health Insurance Portability and Accountability Act (HIPAA)
 National Health Service (NHS)
 United States Food and Drug Administration (USFDA)

Traversing a digital therapeutic from the R&D stage to the market is a long process. The various developmental stages involved in this process have been discussed in detail in the following sections.
 Discovery and Preclinical Phase: The discovery phase involves the identification of a novel digital therapeutic intervention. At this stage, researchers publish their work in academic journals and continue to investigate the potential applications of their digital solutions in disease treatment / management.

 Clinical Trials and Validation: This phase involves the conduct of proper clinical trials to validate the claims made by a digital therapeutic solution providers, and to evaluate its potential in a real-world setting. It includes testing of the software / hardware on a specific patient population. In case of clinical studies, health outcomes are measured and tracked through data driven insights provided by the software. Disease specific improvements (post application / implementation of the intervention) are also tracked to evaluate the performance of a product. There are multiple challenges associated with conducting clinical trials for digital therapeutics. Firstly, technologies are known to change rapidly and there is a very high probability for a software to undergo upgrades / improvements over the duration of a clinical trial. As a result, there are technical issues in storing and updating patient data. Secondly, digital interventions cannot be studied in a double-blind manner, because the investigator is always aware of whether a trial subject is in the control group or being treated with the intervention under evaluation. Finally, at present, there is less structure and guidelines available, and as a result meaningful and conclusive insights are difficult to be drawn from such trials.

 Negotiations with Insurance Providers / Payers: Post the successful completion of clinical studies, developer companies generally tend to avail reimbursement opportunities for their products in order to promote the use of their proprietary solutions and provide financial benefits to patients / consumers. As is the case with pharmacological interventions, reimbursement plans for these products can be achieved based on the outcomes of clinical trials and depending on the USFDA’s (or the concerned regulatory authority of a particular region) clearance. A number of health insurance providers, such as Medicare and Humana, are actively working to include digital therapeutics as a part of health insurance coverage plans for patients suffering from chronic diseases.

 Distribution and Marketing: The pharmaceutical and medical device distribution / marketing system is an established network with well-defined channels through which manufacturers can reach the end-users of their products. Product developers in this domain are presently looking to create a distribution network to sell their offerings in the market via both B2B (healthcare providers, regulators and payers) and B2C (customer) models.

About Roots Analysis
Roots Analysis is a global research and consulting powerhouse specializing in Healthcare, Pharmaceutical, Biotech, Semiconductors, Chemicals and ICT industry. With over a decade of experience, they’ve supported more than 750 clients — spanning Fortune 500 companies, innovative startups, academic institutions, VCs, and strategic investors.
Why Use Roots Analysis in era of Artificial Intelligence?

1. Tailored Insights
2. Robust Methodology
3. Smart Decisions Made Easy
   By combining world-class domain expertise, careful data gathering, and dialogue with senior industry experts, Roots Analysis ensures their deliveries are trustworthy, actionable, and aligned with strategic priorities. The value proposition generated on insights generated by Roots Analysis team is unparalleled in the market research industry.
   Services Offered:
4. Consulting Services (custom insights supporting strategic and tactical requirements, off-the-shelf ready to consume work)
   Roots Analysis offers bespoke consulting services tailored to the unique needs of clients in the life sciences and healthcare sectors.

They specialize in market assessments, tracking industry trends, dynamics, and competitive positioning. These insights help companies fine-tune their product strategies and market-entry plans.

https://www.rootsanalysis.com/reports/digital-therapeutics-market/208.html

Roots Analysis also delivers expert guidance on partnerships, licensing, and investment opportunities. Their strategic support extends to KOL identification, publication analysis, and regulatory intelligence, making them a valuable partner in business growth and innovation.

2. Subscription Services (bundled services supporting multiple topics and domains for a firm)

With their subscription plans, Roots Analysis provides seamless access to a vast library of market intelligence reports. Subscribers enjoy unlimited downloads in multiple formats.

The service includes on-demand research support—allowing clients to request tailored insights and initiate custom research topics. This ensures that emerging needs are met quickly and effectively.

Each subscription comes with a dedicated account manager and direct access to analysts. Flexible billing options and tiered plans make this service suitable for organizations of all sizes seeking continuous, reliable insights.

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: [email protected]
Website: https://www.rootsanalysis.com/